RNS Number : 9299B
Oncimmune Holdings PLC
17 February 2022

17 February 2022




Oncimmune Holdings plc

("Oncimmune" or the "Company")


EarlyCDT® Lung test approved by Ministry of Health for Aragon, Spain
and set to be adopted in the University Hospital Miguel Servet, Zaragoza



Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today notes the Regional Ministry of Health for Aragon, Spain has announced1 that the Company's Early CDT® Lung blood test is to be adopted by the Thoracic Surgery Unit of the University Hospital Miguel Servet, Zaragoza, for use on solitary pulmonary nodules. This approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System having met the necessary criteria with regards to efficacy and safety.


The issuing of this positive assessment by the Aragon Public Health Service and the subsequent approval is considered an important development by Oncimmune and its Spanish distributor, Sabartech, towards the adoption of the blood test by other regional public health systems in Spain.


This latest approval in Spain follows an earlier announcement on 2 November 2021 that EarlyCDT Lung had been authorised for use within the Spanish Public Health Service by the Galician Health Service (SERGAS), the first public health service in Spain to use the EarlyCDT Lung test.


Dr Adam M Hill, CEO of Oncimmune said: "We are pleased with the progress being made by our Spanish distributor, Sabartech, towards the wider adoption of the EarlyCDT blood test within the Spanish public health system. The progress being made in Spain is mirroring the positive engagement we are experiencing with several NHS Clinical Commissioning Groups and Cancer Alliances in the UK. Overall, this is an encouraging development for the continued adoption of the EarlyCDT Lung blood test with national health systems globally."




For further information:


Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer



Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000


WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321


Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis


+44 (0)20 3727 1000




About Oncimmune


ImmunoINSIGHTS Service Business


Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.


Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients.


The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.


EarlyCDT Product Business


Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.


EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells.


EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).


Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.


For more information, visit www.oncimmune.com


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.